Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 16 articles:
HTML format

Single Articles

    June 2022
  1. SANDS BE, Irving PM, Hoops T, Izanec JL, et al
    Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Lancet. 2022;399:2200-2211.
    PubMed     Abstract available

  2. CHAPMAN TP, Satsangi J
    Head-to-head biologic therapy in Crohn's disease.
    Lancet. 2022;399:2169-2171.

  3. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.

    May 2022
  4. FERRANTE M, Panaccione R, Baert F, Bossuyt P, et al
    Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Lancet. 2022;399:2031-2046.
    PubMed     Abstract available

  5. D'HAENS G, Panaccione R, Baert F, Bossuyt P, et al
    Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    Lancet. 2022;399:2015-2030.
    PubMed     Abstract available

  6. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.

  7. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    PubMed     Abstract available

    Upadacitinib for ulcerative colitis.
    Lancet. 2022 May 26. pii: S0140-6736(22)00778.

    August 2021
  9. MCLORNAN DP, Pope JE, Gotlib J, Harrison CN, et al
    Current and future status of JAK inhibitors.
    Lancet. 2021;398:803-816.
    PubMed     Abstract available

    July 2021
  10. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.

  11. SMERAT T, Khdour M, Abdoh Q, Hallak H, et al
    Assessment of health-related quality of life in patients with inflammatory bowel disease in occupied Palestinian territory: a correlation cross-sectional study.
    Lancet. 2021;398 Suppl 1:S48.
    PubMed     Abstract available

    June 2021
  12. HOLMER AK, Singh S
    Expanding targeted immune modulators in ulcerative colitis.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00891.

  13. FEAGAN BG, Danese S, Loftus EV Jr, Vermeire S, et al
    Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00666.
    PubMed     Abstract available

    March 2020
  14. KOSKENVUO L, Sallinen V
    Is preoperative bowel preparation always superfluous? - Authors' reply.
    Lancet. 2020;395:782.

    January 2020
  15. DAMAS OM, Abreu MT
    Are patients with ulcerative colitis still at increased risk of colon cancer?
    Lancet. 2020;395:92-94.

  16. OLEN O, Erichsen R, Sachs MC, Pedersen L, et al
    Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study.
    Lancet. 2020;395:123-131.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.